Biochemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
Biochemotherapy leads to lower progression‐free survival† compared with chemotherapy (high certainty).
Biochemotherapy leads to higher tumour response compared with chemotherapy (high certainty).
Biochemotherapy leads to higher toxicity (≥ G3) compared with chemotherapy (high certainty).
Polychemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
Polychemotherapy showed no clear difference in progression‐freesurvival† compared with chemotherapy (high certainty).
Polychemotherapy probably leads to higher tumour response compared with chemotherapy (moderate certainty).
Polychemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).
Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether neoadjuvant immunotherapy (high dose interferon) plus chemotherapy changes overall response rate (ORR), measured after 8 weeks of treatment and… compared with neoadjuvant chemotherapy (very low certainty).
The review found no eligible studies for this question.